Article
Biochemistry & Molecular Biology
Andrzej Kowalski, Katarzyna Malinowska, Jurek Olszewski, Hanna Zielinska-Blizniewska
Summary: The interaction of PD-1 and PD-L1 in laryngeal tumors allows cancer cells to escape from the immune system. Gene expression of PD-1 and PD-L1 was significantly higher in tumor tissue compared to unchanged mucosa, with higher expression levels associated with larger tumor sizes. These findings suggest potential for targeted immunotherapy with anti-PD1 and anti-PD-L1 monoclonal antibodies in treating laryngeal tumors.
Review
Oncology
Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou Huang, Mohammad Reza Karimzadeh, Amir Abaas Momtazi-Borojeni, Sheng Chen
Summary: Exosomes, specifically those derived from cancer cells, contain immunosuppressive proteins such as PD-L1, which can hinder immune responses and promote tumor progression. Blocking the interaction between PD-1 and PD-L1 can enhance the efficacy of cancer treatment by restoring anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Rilan Bai, Jiuwei Cui
Summary: Antibodies targeting PD-1/PD-L1 have been considered breakthrough therapies for cancer. In addition to T cell-driven immune responses, blocking PD-1/PD-L1 may also enhance the function and activity of NK cells, which are often overlooked in previous studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ruizhe Wang, Yi Zhang, Fengping Shan
Summary: Cervical cancer, a major threat to women's health and lives worldwide, can be effectively treated with immunotherapy using PD-L1 inhibitors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Chunyi Shen, Zhen Zhang, Yonggui Tian, Feng Li, Lingxiao Zhou, Wenyi Jiang, Li Yang, Bin Zhang, Liping Wang, Yi Zhang
Summary: The study demonstrated that combining SFN with CAR-T cells enhanced cytotoxicity and antitumor functions by modulating the PD-1/PD-L1 pathway, suggesting a promising strategy for cancer immunotherapy.
Review
Immunology
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li
Summary: Leukemia cells induce immunosuppression of the bone marrow microenvironment, preventing the immune system from clearing tumor cells. The PD-1/PD-L1 axis acts as a significant mechanism for tumor cells to evade immune surveillance. The development of drugs targeting PD-1/PD-L1 in leukemia is still at the clinical-trial stage.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
April A. N. Rose, Susan M. Armstrong, David Hogg, Marcus O. Butler, Samuel D. Saibil, Diana P. Arteaga, Thiago Pimentel Muniz, Deirdre Kelly, Danny Ghazarian, Ian King, Zaid Saeed Kamil, Kendra Ross, Anna Spreafico
Summary: The study found that primary melanoma tumor type and genomic subtype serve as independent predictive markers of clinical progression-free survival and overall survival in patients with metastatic melanoma receiving anti-PD1 ICI. Further evaluation in prospective clinical trials is needed to determine the value of primary tumor type and genomic subtype, including NRAS, as predictive markers. Biologic subtypes may aid in clinical decision-making when deciding between combination ICI treatment (anti-PD1 +/- anti-CTLA4) versus anti-PD1 alone for patients with metastatic melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Medicine, General & Internal
Jun Xu, Jianguo Zhao, Jianfang Wang, Caiping Sun, Xiaoling Zhu
Summary: This meta-analysis suggests that a higher pretreatment LDH level is significantly associated with worse overall survival and shorter progression-free survival in melanoma patients receiving anti-PD1/PD-L1 monotherapy.
Article
Oncology
Julie Niogret, Helene Berger, Cedric Rebe, Romain Mary, Elise Ballot, Caroline Truntzer, Marion Thibaudin, Valentin Derangere, Christophe Hibos, Lea Hampe, David Rageot, Theo Accogli, Philippe Joubert, Bertrand Routy, James Harker, Frederique Vegran, Francois Ghiringhelli, Fanny Chalmin
Summary: Tfh cells play an important role in antitumor immune response, especially in a CD8(+)-dependent manner, by producing interleukin-21 to support the function of exhausted T cells. Their accumulation in tumor sites and draining lymph nodes is closely associated with treatment efficacy and patient survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Tingting Zhang, Hengqi Liu, Lei Jiao, Zhenzhen Zhang, Jin He, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Wenchen Gong, Bin Meng, Xiubao Ren, Huilai Zhang, Xianhuo Wang
Summary: This study identifies a new genetic basis for PD-L1 overexpression and characterizes certain genetic alterations of CD73/A2aR in DLBCL. The degree of T-cell dysfunction is correlated with clinical outcomes. Therefore, strategies that inhibit PD-1/PD-L1/L2 and combine with CD73/A2aR to reverse T-cell dysfunction may serve as effective therapeutic options for DLBCL.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Xiao-Jun Guo, Jia-Cheng Lu, Hai-Ying Zeng, Rong Zhou, Qi-Man Sun, Guo-Huan Yang, Yan-Zi Pei, Xian-Long Meng, Ying-Hao Shen, Peng-Fei Zhang, Jia-Bin Cai, Pei-Xin Huang, Ai-Wu Ke, Ying-Hong Shi, Jian Zhou, Jia Fan, Yi Chen, Liu-Xiao Yang, Guo-Ming Shi, Xiao-Yong Huang
Summary: The study found that in ICC tumors, CTLA-4(+) lymphocyte density was elevated compared to peritumoral hepatic tissues, and patients with high CTLA-4(+) tumor-infiltrating lymphocytes (TILs(CTLA-4 High)) had lower overall survival rates and higher cumulative recurrence rates. High FOXP3(+) TILs (TILs(FOXP3 High)) were associated with poorer prognoses, and the density of CTLA-4(+) TILs was positively correlated with FOXP3(+) TILs. High PD-L1 expression in tumors (Tumor(PD-L1 High)) and/or TILs(CTLA-4 High) were also linked to worse outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Taisuke Kaiho, Hidemi Suzuki, Atsushi Hata, Hiroki Matsumoto, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Summary: Immune checkpoint molecules, such as PD-1 and PD-L1, have been shown to be important in lung cancer treatment. This study explored the role of these proteins in acute rejection in a mouse model of tracheal transplantation and found that PD-L1 Fc recombinant protein could decrease inflammatory cytokines and reduce the proportion of CD4+ T cells, suggesting a potential novel target for immunotherapy in lung transplantation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Fereshteh Ameli, Elham Shajareh, Maral Mokhtari, Farid Kosari
Summary: This study aimed to evaluate the expression of PD-1 and PD-L1 in MCL specimens and found that neither PD-1 nor its ligands represent relevant targets for MCL treatment. Additionally, the percentage of PD1 positive tumor cells was negatively correlated with patient age.
Review
Oncology
David Johnson, Brigette B. Y. Ma
Summary: The upregulation of the PD-1/PD-L1 pathway is a possible immune-evasion mechanism in Epstein-Barr virus-associated nasopharyngeal cancer (NPC). Therapeutic targeting of this pathway is actively researched in NPC, with multiple monoclonal antibodies currently under evaluation in clinical settings. Combinatorial strategies involving cytotoxic chemotherapy, radiotherapy, and other immunotherapeutic agents are also being explored in clinical trials for NPC.
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Koen Degeling, Nancy N. Baxter, Jon Emery, Mark A. Jenkins, Fanny Franchini, Peter Gibbs, G. Bruce Mann, Grant McArthur, Benjamin J. Solomon, Maarten J. IJzerman
Summary: The study shows that the COVID-19 pandemic has delayed cancer diagnosis and treatment, impacting survival outcomes and healthcare costs. Based on Australian data, even a conservative once-off 3-month delay is predicted to result in 88 excess deaths and $12 million excess healthcare costs.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
P-J. Souquet, S-W. Kim, B. Solomon, J. F. Vansteenkiste, M. Carbini, A. Jary, S. Glaser, A. Chassot Agostinho, J. Wolf
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Sai-Hong Ou, Benjamin J. Solomon, Alice T. Shaw, Shirish M. Gadgeel, Benjamin Besse, Ross A. Soo, Antonello Abbattista, Francesca Toffalorio, Robin Wiltshire, Alessandra Bearz
Summary: This study retrospectively analyzed the clinical benefit of continuing Lorlatinib beyond progressive disease in patients with ALK-positive NSCLC. The results showed that continuing LBPD can be a viable treatment strategy for these patients.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
D. S-W. Tan, M. Thomas, D-W. Kim, S. Szpakowski, P. Urban, R. Mehra, L. Q. M. Chow, S. Sharma, B. J. Solomon, E. Felip, D. R. Camidge, J. Vansteenkiste, L. Petruzzelli, S. Pantano, A. T. Shaw
Summary: An exploratory analysis was conducted to understand the genetic determinants of response to ceritinib in ALK+ NSCLC patients. The study revealed the potential role of next-generation sequencing (NGS) in improving our understanding of response and resistance to ceritinib. It also demonstrated the efficacy of ceritinib against almost all ALK resistance mutations found in ALKi-pretreated patients.
Article
Oncology
B. J. Solomon, H. H. Loong, Y. Summers, Z. M. Thomas, P. French, B. K. Lin, A. Sashegyi, J. Wolf, J. C-H Yang, A. Drilon
Summary: This study identified a strong correlation between the treatment effects on ORR and PFS in randomized clinical trials targeting oncogene-addicted tumors, while a weaker correlation was observed between ORR and OS.
Article
Oncology
Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Summary: BRAF V600E mutant metastatic colorectal cancer is a significant clinical problem. Combination therapy with vemurafenib and small-molecule EGFR inhibitors has shown effectiveness in pre-clinical studies, but clinical investigation is lacking.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip
Editorial Material
Oncology
Trudy C. Wu, Annalise Stube, Carol Felix, Denise Oseguera, Tahmineh Romero, Jonathan Goldman, Edward B. Garon, Jay M. Lee, John Glaspy, Aaron E. Lisberg, Chad G. Rusthoven, D. Ross Camidge, Shankar Siva, Benjamin Solomon, Alan Lee, Stephen E. Tenn, Narek Shaverdian, Michael L. Steinberg, Ann C. Raldow, Percy Lee
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Letter
Oncology
Nicolas Girard, Marina C. Garassino, Benjamin Solomon
JOURNAL OF THORACIC ONCOLOGY
(2023)
Letter
Oncology
Nicolas Girard, Marina C. Garassino, Benjamin Solomon
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Ross A. Soo, Jean-Francois Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, Deborah Shepard, Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao-Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin J. Solomon
Summary: In treatment-naive patients with advanced ALK-positive NSCLC, ctDNA can be used as a biomarker to predict the efficacy of lorlatinib treatment.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Medicine, General & Internal
Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne -Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jurgen Wolf, Martin Schuler, Herve Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang-We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Bjorn Stollenwerk, David Waterhouse, Luis Paz-Ares
Summary: This study compared the efficacy and safety of Sotorasib with standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The results showed that compared to docetaxel, Sotorasib significantly increased progression-free survival and had a more favorable safety profile.
Review
Oncology
Grace Chazan, Benjamin J. Solomon
Summary: First-line treatment options for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have evolved rapidly. Although newer generation ALK inhibitors have demonstrated superiority to crizotinib, head-to-head clinical trials comparing these inhibitors are lacking. Decisions on optimal first-line treatment must be based on analysis of relevant trials and consideration of various factors.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Review
Medicine, General & Internal
L. B. Cameron, N. Hitchen, E. Chandran, T. Morris, R. Manser, B. J. Solomon, V Jordan
Summary: This study evaluated the safety and efficacy of ALK inhibitors as monotherapy for advanced ALK-rearranged NSCLC. The results showed that ALK inhibitors are effective in improving progression-free survival, overall survival, and overall response rate, with minimal adverse events compared to chemotherapy. Next-generation ALK inhibitors are more effective and safe than first-generation ALK inhibitors. However, further research is needed to compare different next-generation ALK inhibitors.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Endocrinology & Metabolism
Ray Wang, Benjamin Solomon, Stephen J. Luen, Owen W. J. Prall, Christine Khoo, Anthony J. Gill, Jeremy Lewin, Nirupa Sachithanandan
Summary: Adrenocortical carcinoma is a rare disease with significant clinical heterogeneity, presenting a diagnostic challenge to clinicians. Specialist multidisciplinary team input and genomics play vital roles in diagnosis and prognosis of adrenocortical carcinoma.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS
(2022)